PDS Biotechnology Narrows Q1 Loss to $7.3M, Amends Phase 3 PFS Endpoint
PDSB•PDS Biotechnology posted a Q1 net loss of $7.3M ($0.13/shr) versus $8.5M ($0.21/shr) a year earlier, cut R&D to $3.5M and ended March with $21.7M cash. Amended VERSATILE-003 Phase 3 trial to add PFS as interim endpoint and saw a 77.8% ORR in the metastatic colorectal PDS01ADC trial.
1. First-Quarter Financial Results
PDS Biotechnology reported a net loss of $7.3 million for Q1, or $0.13 per share, compared with a $8.5 million loss, or $0.21 per share, in the prior-year period. Research and development expenses declined to $3.5 million from $5.8 million, while general and administrative costs edged down to $3.1 million.
2. Clinical Development and Corporate Update
The company amended its VERSATILE-003 Phase 3 protocol to include progression-free survival as an interim primary endpoint, enabling a potential accelerated approval pathway for PDS0101. In the Stage 1 metastatic colorectal PDS01ADC trial, it achieved a 77.8% objective response rate, and early mCRPC data showed a median PFS of 9.6 months with a 40% median PSA decline.
3. Cash Position and Upcoming Webcast
PDS Biotechnology concluded Q1 with $21.7 million in cash and reported net interest expense of $0.8 million. Management will host an investor webcast on May 13, 2026 at 8:00 a.m. ET to discuss the quarter’s results and clinical progress.
